Idenix Pharmaceuticals (IDIX)
Idenix Pharmaceuticals SG&A Expense: 4.774M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IDIX SG&A Expense Rankings
| Overall | 79th percentile | 855 of 4190 |
| Sector | 61st percentile | 187 of 485 in Healthcare |
| Industry | 45th percentile | 84 of 153 in Biotechnology |
IDIX SG&A Expense Range, Past 5 Years
| Minimum | 3.90M | Sep 2011 |
| Maximum | 19.84M | Jun 2007 |
| Average | 7.051M |
About SG&A Expense
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
Learn More
You may also be interested in these IDIX related companies
IDIX News
@johnkelly $IDIX Montruous activity today as well, something is going on.
about 22 hours ago by littleguy
about 22 hours ago by littleguy
thu $IDIX hype seemz 2 have reeturned. huge call volume on OTM callz yesterday. pickin up sum ITMs 2day
about a day ago by johnkelly
about a day ago by johnkelly
$IDIX HighGrowthFinancial told me a few weeks ago after it hit 9.35 and went back to 785ish that the chart looked good and dont worry.
about a day ago by GArgondizza
about a day ago by GArgondizza
$IDIX Option Bulls Take Another Shot on Idenix. Pete Najarian. http://stks.co/3zAL
about a day ago by littleguy
about a day ago by littleguy
$IDIX Any buyout talk? I'd like to hit the INHX, Pharmasset, Idenix trifecta. Nobody likes Hep C more than me
about a day ago by Grossgrossgross
about a day ago by Grossgrossgross
$IDIX where is EXP. yeah. Calls expired worthless a while ago but long 3000 shares in the 11's
about 2 days ago by PeruvianKnightmare
about 2 days ago by PeruvianKnightmare
$IDIX still marching, spending more confirmation time on da BULLS side
about 2 days ago by HighGrowthFinancial
about 2 days ago by HighGrowthFinancial
Brean Murray Sees Recent Upside in Idenix (IDIX) Related to Possible Gilead (GILD) Settlement in June
May 24, 5:14PM Street Insider
May 24, 5:14PM Street Insider
@GArgondizza @johnkelly Why the love affair with $IDIX today? Don't see any news pending.
about 2 days ago by PattyA_F
about 2 days ago by PattyA_F
$IDIX Getting a bit extended! Be careful, stay disciplined! http://chart.ly/veumy3r
about 2 days ago by TeejTime2
about 2 days ago by TeejTime2
Idenix Pharma having a nice day today and trending on StockTwits into the close http://stks.co/3yjY $IDIX
about 2 days ago by StockTwits
about 2 days ago by StockTwits
from a month ago.. taking its sweet time RT @BlackBetty $IDIX temp target 10.7
about 2 days ago by BlackBetty
about 2 days ago by BlackBetty
Idenix Pharmaceuticals' CEO Presents at Deutsche Bank 37th Annual Healthcare Conference (Transcript)
May 07, 7:46PM Seeking Alpha
May 07, 7:46PM Seeking Alpha
Idenix Pharmaceuticals Reports First Quarter 2012 Financial Results and HCV Development Program Progress
May 02, 4:05PM GlobeNewswire
May 02, 4:05PM GlobeNewswire
Idenix Pharma (IDIX) Rips, Reports Encouraging Data from IDX719 Phase I
Apr 19, 9:21AM Street Insider
Apr 19, 9:21AM Street Insider
Idenix Pharmaceuticals Provides Update on Hepatitis C Clinical Development Programs
Apr 19, 7:53AM Benzinga
Apr 19, 7:53AM Benzinga
Credit Suisse Assumes Coverage on Idenix Pharmaceuticals Inc. (IDIX) at Neutral
Apr 17, 7:47AM Street Insider
Apr 17, 7:47AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDIX | 9.68 | -0.40 | -3.97% | 1.041B |
| ICGE | 8.79 | -0.11 | -1.24% | 329.98M |
| ICF | 75.36 | -0.33 | -0.44% | |
| ICCC | 5.950 | -0.00 | -0.00% | 17.97M |
| IBM | 194.30 | -1.79 | -0.91% | 225.13B |
| IBKR | 14.38 | +0.23 | +1.63% | 655.44M |
| IBKC | 48.84 | -0.36 | -0.73% | 1.436B |
| IBI | 17.94 | -0.18 | -0.99% | 566.90M |
| IBCP | 3.35 | -0.01 | -0.30% | 28.61M |
| IBA | 20.55 | +0.53 | +2.65% | 1.028B |